Featured Research

from universities, journals, and other organizations

Lung cancer: Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial

Date:
July 7, 2011
Source:
International Association for the Study of Lung Cancer
Summary:
Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to new research.

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

Related Articles


"Amrubicin showed significant improvements in tumor shrinkage, symptom control and progression-free survival over topotecan without improving overall survival, the primary endpoint of the trial," said principal investigator Dr. Joachim von Pawel, of the Asklepios Hospital Munich-Gauting in Germany. "However, for patients with the most difficult-to-treat small cell lung cancer, amrubicin offered an improvement in overall survival compared with topotecan."

Second-line treatment is given to patients after the initial, or first-line, treatment has failed.

In the study, 637 patients were randomized to amrubicin or to topotecan. Patients on amrubicin reported better symptom control and quality of life (Lung Cancer Symptom Scale 0.2 vs 5.6 and LCSS-SB -0.1 vs 5.2 for amrubicin and topotecan, respectively). They also reported fewer adverse events, including neutropenia (41% vs 53% for the topotecan arm), thrombocytopenia (21% vs 54%), anemia (16% vs 30%), infections (16% vs 10%), febrile neutropenia (10% vs 4%), all P<0.05, and cardiac disorders (5% vs 5%; P=0.84).

Dr. Joachim von Pawel discussed the research at the conference.


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Lung cancer: Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial." ScienceDaily. ScienceDaily, 7 July 2011. <www.sciencedaily.com/releases/2011/07/110707081935.htm>.
International Association for the Study of Lung Cancer. (2011, July 7). Lung cancer: Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2011/07/110707081935.htm
International Association for the Study of Lung Cancer. "Lung cancer: Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial." ScienceDaily. www.sciencedaily.com/releases/2011/07/110707081935.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins